---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-21-032109"
form_type: "8-K"
ticker: "LCTX"
cik: "0000876343"
company_name: "Lineage Cell Therapeutics, Inc."
filed_at: "2021-12-21T23:59:59+00:00"
generated_at: "2026-06-27T23:31:59.561523+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Lineage Cell Therapeutics launches new $64.1M at-the-market equity offering

## Summary
- Prior $25M ATM program terminated; $14.1M remained unsold.
- New ATM allows sale of up to $64,133,000 of common shares via Cantor Fitzgerald.
- Shares registered under May 2020 and March 2021 shelf registration statements.
- Legal opinion of Cooley LLP filed as Exhibit 5.1; proceeds not specified.

## SEC filing metadata
- accession: 0001493152-21-032109
- form_type: 8-K
- ticker: LCTX
- cik: 0000876343
- company_name: Lineage Cell Therapeutics, Inc.
- filed_at: 2021-12-21T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/876343/000149315221032109/0001493152-21-032109-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/876343/000149315221032109/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-21-032109
- JSON: https://secwatch.observer/filing/0001493152-21-032109.json
- Plain text: https://secwatch.observer/filing/0001493152-21-032109.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.